Health Economics›Bladder cancer›Locally advanced or metastatic disease, maintenance after platinum chemotherapy

Locally advanced or metastatic disease, maintenance after platinum chemotherapy

Bladder cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	5.4 mo	—	12	R 3 443 463 PFS proxy	1
Avelumab monotherapy N/A - secondary systemic drug	—	R 0	28d	—	23.8 mo	—	—	1

2 of 2 regimens shown